Ingredients/Content

Active ingredients: 1 tablet Valacyclovir 500mg

Efficacy/Effectiveness

Valacyclovir is effective in treating primary and recurrent genitinitis infections, and is also effective in papillary and shingles. It is also applied to suppress the recurrence of genitinitis infection, and is used as an inhibitory therapy to reduce the transmission of genitinitis when a safe sex life is combined. In addition, it is used to prevent against giant cell viral infection after kidney transplantation and to treat chickenpox in children aged 2 to 18 with normal immune functions. There are products such as Baltrex®.

Usage/Capacity 

1. An adult

1) shingles

Oral administration of 1,000 mg once as valacyclovir, 3 times a day, for 7 days

2) an infectious disease of genital plexus

As this drug, 500 mg is administered twice a day.

In the case of recurrence, it can be administered for 5 days, and in the case of first onset, it can be administered for up to 10 days if the symptoms are severe.

It's better to start treatment as soon as possible.

In the case of recurrent herpes simplex, it is most effective to administer as soon as prodromal symptoms or symptoms/signs appear for the first time.

This drug can prevent lesion deterioration when the symptoms/signs of recurrent genitourinary papules first appear.

3) Suppression of recurrence of genocidal infection

(1) a patient with normal immune function

The total daily dose is 500 mg as this drug, and 250 mg can be administered twice a day.

Administration of 500 mg once a day and once a day is also effective, especially in patients who relapse less than 10 times a year.

For some patients who relapse more than 10 times per year without treatment, an additional benefit can be obtained from the split administration of 250 mg twice a day (total dose of 500 mg per day) as this drug.

Treatment should be reevaluated after 6 to 12 months of administration.

(2) Patients with decreased immune function: administer 500 mg once twice a day as this drug.

4) a decrease in transmission of genitourinary papules

For heterosexual adults with normal immune functions who relapse less than nine times a year: Infected sex partners should take 500 mg once a day as this drug to reduce transmission to sexual partners with negative Herpes Simplex Virus-2 (HSV-2) antibodies.

Safe sex life (especially using condoms) should be maintained, and sexual contact should be avoided if lesions appear.

5) prevention of cytomegalovirus infection

As this drug, 2,000 mg is taken four times a day, and administration is started within 72 hours after transplantation or as soon as it can be taken.

The dose should be reduced according to the creatinine clearance rate.

The duration of administration is usually 90 days, but extension may be necessary for high-risk patients.

6) nine-shot wound

The recommended dose of this drug for the treatment of papillary spores is this drug, administering 2,000 mg once twice a day for 1 day at 12 hours intervals

As soon as early signs of papillary spores (e.g., numbness, itchiness, and burning) appear, medication should be administered.

The efficacy of administering this drug has not been established since the clinical symptoms of papules (e.g., papules, follicles, ulcers) appeared.

2. A child

1) Prevention of giant cell virus infection (over 12 years old)

As this drug, 2,000 mg is taken four times a day, and administration is started within 72 hours after transplantation or as soon as it can be taken.

The dose should be reduced according to the creatinine clearance rate.

The duration of administration is usually 90 days, but extension may be necessary for high-risk patients.

2) Gusunpojin (over 12 years old)

The recommended dose for treating papillary spores is this drug, administering 2,000 mg once twice a day for 1 day at 12 hours intervals

As soon as early signs of papillary spores (e.g., numbness, itchiness, and burning) appear, medication should be administered.

The efficacy of administering this drug has not been established since the clinical symptoms of papules (e.g., papules, follicles, ulcers) appeared.

3) Chickenpox of children aged 2 to 18 years old: administer 20 mg once 3 times a day for 5 days as a medicine per kg of body weight

The total dose shall not exceed 1,000 mg once, three times a day.

Treatment should be started as soon as initial signs or symptoms appear.

According to the efficacy data of the clinical trial of oral Valacyclovir, administration should be started within 24 hours of the onset of rash.

3. A senior citizen

1) When exposure to acyclovir, an active metabolite of this drug, increases, the risk of developing psychoneuropathy or renal dysfunction increases.

In patients with renal impairment, patients with renal impairment, and elderly people, the administration interval and dosage of this drug are controlled and carefully administered while observing the patient's clinical condition.

2) Dose control is not required unless renal function is specifically impaired.

Proper hydration should be maintained.

4. A patient with renal dysfunction

Patients with significantly impaired renal function should control the dose as follows.

Proper hydration should be maintained.

There are no data on the administration of this drug in pediatric patients with creatinine clearance rates below 50 mL/min/1.73 m2.

In the case of hemodialysis patients, it is administered after hemodialysis is completed.

The creatinine clearance rate should be frequently monitored during periods of rapid changes in kidney function (e.g., immediately after transplantation or kidney transplantation)

The dosage of this drug should be properly adjusted according to the creatinine cleaning rate.

5. A peritoneal dialysis patient

There is no information on the administration of this drug in patients undergoing peritoneal dialysis.

The effects of chronic portable peritoneal dialysis (CAPD) and continuous arteriovenous blood filtration/dialysis (CAVHD) on the pharmacokinetics of acyclovir were tested.

The excretion of acyclovir after CAPD and CAVHD was found to be less than when he was hemodialysis

The pharmacokinetic variables were very similar to those observed in patients with end-stage renal disease not receiving hemodialysis.

Therefore, adjuvant administration of this drug is not necessary after CAPD or CAVHD (see the section on careful administration for the next patient)

6. A patient with liver dysfunction

In patients with mild to moderate cirrhosis (patients with normal liver synthetic function), no separate dose control is required.

For patients with severe cirrhosis (synthetic dysfunction of the liver, patients with signs of portal vein-tolerant anastomosis)

According to hemodynamic data, separate dose control is not required, but clinical experience is insufficient.

Therefore, this drug should be carefully administered when administering high doses to patients with liver dysfunction (see section on carefully administering it to the next patient)

Precautions for use

Drink enough water to reduce the effect on renal function. In particular, patients who are concerned about dehydration should be administered with care, such as properly supplying moisture.

Since acyclovir, an active metabolite of valacyclovir, is excreted through the kidneys, it should be reviewed whether dose reduction is necessary for patients with renal impairment and elderly patients with renal impairment. In addition, both elderly patients and patients with renal impairment have an increased risk of neurological adverse reactions, so carefully observe them. In general, it has been reported that stopping valacyclovir administration can lead to recovery.

Care should be taken when administering in high doses to patients with liver dysfunction.

Although valacyclovir can be used for the purpose of preventing genocidal transmission, it does not completely eliminate the risk of transmission. Therefore, a safe sex life such as using condoms is recommended along with the administration of valacyclovir.

Carefully administered when administering valacyclovir to women, lactating women, and elderly people who may be pregnant or pregnant.

Side effects

Common side effects (reported in more than 10% of users) headache, nausea, abdominal pain, increased serum AST, nasopharyngitis

Common side effects (reported in 1 to 10% of users) fatigue, depression, dizziness, skin rash, dehydration, nausea, diarrhea, dysmenorrhea, hypovascularization, leukopenia, simple herpes infection, joint pain, runny nose, fever

Rare side effects (reported in less than 1% of users) Aggressive behavior, anxiety, hair loss, anemia, regenerative anemia, malaise, confusion, dysphagia, polymorphic erythema, facial edema, hallucinations, hepatitis, hypersensitivity, hypertension, irritable vasculitis, elevated serum creatinine, loss of consciousness, renal failure, redness, skin photosensitivity, tachycardia, progression, urgent urination, visual impairment

Storage method

Store at room temperature (1-30℃), shielded airtight container

etc

We encourage you to consult with your doctor before your personal income to gain sufficient knowledge of your medicines.

Manufacturer

Cipla